Top Manufacturing Companies in Dublin (54)
TEAM Accessories (TA) is an independent aerospace MRO provider with overhaul capabilities on engine accessories, airframe components and airframe safety equipment. TA also have overhaul capabilities on a wide range of industrial gas turbine accessories and components servicing the oil & gas and energy sector. 25 years’ experience supporting a global customer base with bespoke service solutions. Certified Approvals: EASA/...
NIBCO is a leading manufacturer and provider of flow control solutions, including valves, piping, and fittings, for residential, commercial, industrial, and municipal markets.
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in...
Ipsen's Top Stability & Growth Strengths
Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.
Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.
Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our...
Atlas is a leading designer and manufacturer of autonomous UAV systems for professional use-cases, that works with a dominant defense, security, and infrastructure institutions in the U.S., the E.U., and Asia. Founded in the EU in 2015 by Aerospace and Robotics professionals with a vision to disrupt the UAV sphere, Atlas utilizes its proprietary and cost-effective technology to provides defense...
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal...
Applied Materials is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future.
Applied Materials's Top Stability & Growth Strengths
Strong Market Position & Advantage: Applied Materials is widely characterized as a top-tier leader in semiconductor equipment with a broad, diversified front-end portfolio and leadership in critical process areas like deposition. Its global reach and participation across most wafer-fab steps reinforce a durable competitive position.
Strong Revenue Growth: Recent results highlight record quarterly and annual revenue with guidance pointing to further acceleration into 2026. Consistent outperformance versus expectations and raised outlooks indicate building momentum.
Innovation-Driven Growth: Growth is propelled by exposure to AI, leading-edge logic, DRAM, and advanced packaging, with management projecting rapid expansion in these areas through 2026. Significant R&D investment and new capabilities in high-bandwidth memory and advanced packaging support this trajectory.
Uniphar is a diversified healthcare services organisation with activities in Ireland, UK, Europe, the USA and APAC
Invert Robotics provides remote robotic inspection services with unprecedented levels of safety, accuracy and speed. Our main focus is in the Food Production, Chemicals, Pharmaceuticals, Aviation and Energy industries. This is not an everyday job, but a job where safety and accuracy are paramount. Besides this, Invert Robotics comes together with an agile and inventive work environment. At Invert Robotics,...
X-Bolt brings simplicity and efficiency to trauma surgery, whilst improving quality of life for patients
Rakuten Kobo Inc. is the world’s only dedicated digital bookseller. Owned by Tokyo-based Rakuten and headquartered in Toronto, Kobo enables more than 30 million readers worldwide to read anytime, anywhere and on any device. With our award-winning eReaders and the free Kobo App for smartphones and tablets, Kobo is your portable reading world
Edwards is a leading developer and manufacturer of sophisticated vacuum products, abatement solutions and related value-added services. Our products are integral to manufacturing processes for semiconductors, flat panel displays, LEDs and solar cells; are used within an increasingly diverse range of industrial processes including power, glass and other coating applications, steel and other metallurgy, pharmaceutical and chemical; and for both...
Sia Partners is a next generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. Counting 1,800 consultants in 18 countries, we expect to achieve USD 300 million in turnover for the current fiscal year. With a global footprint and expertise...
Sia Partners's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent investment by Blackstone of up to €250 million in December 2024 provides growth capital and signals external confidence in the firm’s expansion plans. Company statements link this funding to accelerating U.S. growth, M&A, and AI-enabled offerings.
Market Expansion: Multiple acquisitions and a sustained U.S. push (e.g., Notion Consulting, Ready Set Rocket, Precedence, Kaiser Associates) indicate ongoing geographic and service-line expansion across North America and Europe. Leadership attention to the U.S. market and a growing office footprint suggest increased depth in key geographies.
Innovation-Driven Growth: The firm is productizing AI (e.g., SiaGPT and 800+ deployable AI agents by April 2026) and launching new lines like Corporate Strategy, PE & M&A, pointing to growth via differentiated, tech-enabled delivery. Partnerships and ecosystem recognition around NVIDIA and AWS reinforce momentum in AI-driven consulting.
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments...
BioMarin Pharmaceutical Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Results show double‑digit revenue growth in 2025, with acceleration in Q4 driven by Voxzogo uptake and steady enzyme therapies across 55 markets. 2026 guidance points to a higher revenue range, indicating continued expansion.
Profitability: Disclosures highlight strong profitability with $828 million in 2025 operating cash flow and a targeted ~40% non‑GAAP operating margin for 2026 (excluding Amicus). Non‑GAAP EPS guidance of $4.95–$5.15 further signals operating leverage.
Diversified Revenue Streams: The portfolio spans multiple enzyme therapies and the achondroplasia franchise, and the pending Amicus acquisition would add Galafold and Pombiliti + Opfolda to diversify revenues from mid‑2026 onward. Enzyme therapies collectively grew in 2025, supporting breadth beyond a single asset.
With an aim of pioneering the zero-emission two-wheeled electric transport revolution, Modmo is a disruptive Irish e-mobility company with offices in Dublin, London and Germany. The Modmo Technology Centre is based in Saigon where our R&D and production team work closely with our factories and have their finger firmly on the pulse of new design and modern production. MODMO exists...
Our Vision: Our intelligent sensing platforms integrated on all plasma and RF processing equipment to enable atomic-scale engineering for the advancement of nano-technology. Our Mission: Creating intelligent sensing platforms for advanced plasma and RF manufacturing processes, to improve process performance and reduce product scrap. Our Purpose: Our company exists because we believe in the science of measurement. We believe that...
Antares is developing compact nuclear microreactors to provide strategic energy for critical mission capabilities on Earth, in space, and underwater, particularly for remote military bases.
